Surveillance of susceptibility of clinical isolates to cefmetazole between 2000 and 2003

Japanese Journal of Antibiotics

Volumn 58, Issue 3, 2005, Pages 303-316

  Sato, Yuki ^a   Abe, Tomomi ^a   Koga, Tetsufumi ^a   Ito, Kazuyoshi ^a   Tochikawa, Yuko ^b  

^a DAIICHI SANKYO CO   (Japan)

^b Institute of Science and Technology Inc

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFMETAZOLE; CEFOTIAM; FLOMOXEF; OXACILLIN; SULPERAZON;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES FRAGILIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; ESCHERICHIA COLI; JAPAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PEPTOSTREPTOCOCCUS; POSTMARKETING SURVEILLANCE; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENCIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BACTEROIDES; CEFMETAZOLE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA; MORGANELLA; PEPTOSTREPTOCOCCUS; PROTEUS MIRABILIS; PROVIDENCIA; STAPHYLOCOCCUS;

EID: 22444436121     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. National Committee for Clinical Laboratory Standards (U.S.A.): Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. NCCLS document M100-S12, 2002
2. National Committee for Clinical Laboratory Standards (U.S.A.): Performance Standards for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Informational Supplement. M100-S13, 2003
3. Jpn. J. Antibiotics 52: 585-594, 1999
4. Jpn. J. Antibiotics 55: 764-770, 2002